Phase 2 Study of Poziotinib in NSCLC with EGFR/HER2 Mutations Underway
A Phase 2 study is evaluating poziotinib's efficacy and safety in NSCLC patients with specific mutations.
Asset / Drug
Drug and asset intelligence for Poziotinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.